Recursion Pharmaceuticals... (RXRX)
NASDAQ: RXRX
· Real-Time Price · USD
5.63
-0.07 (-1.23%)
At close: Aug 14, 2025, 3:59 PM
5.67
0.62%
Pre-market: Aug 15, 2025, 06:20 AM EDT
-1.23% (1D)
| Bid | 5.67 |
| Market Cap | 2.41B |
| Revenue (ttm) | 64.44M |
| Net Income (ttm) | -648.97M |
| EPS (ttm) | -1.81 |
| PE Ratio (ttm) | -3.11 |
| Forward PE | -4.5 |
| Analyst | Hold |
| Ask | 5.68 |
| Volume | 14,563,174 |
| Avg. Volume (20D) | 27,963,100 |
| Open | 5.45 |
| Previous Close | 5.70 |
| Day's Range | 5.41 - 5.69 |
| 52-Week Range | 3.79 - 12.36 |
| Beta | 0.92 |
About RXRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RXRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RXRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Recursion Pharmaceuticals has released their quartely earnings
on Aug 5, 2025:
Next Earnings Release
Recursion Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-4.66%
Recursion Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
1 month ago
+8.72%
Recursion Pharmaceuticals shares are trading higher after the company announced it acquired the joint ENPP1 inhibitor program and associated backup molecule from Rallybio.
